Business Description
Cellectis SA
SIC : 2834
ISIN : FR0010425595
Total Employee Number:
229Compare
Compare
Traded in other countries / regions
ALCLS.FranceCLLS.USAZVA.Germany0WA2.UK IPO Date
2007-02-06Description
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.97 | |||||
Equity-to-Asset | 0.15 | |||||
Debt-to-Equity | 2.06 | |||||
Debt-to-EBITDA | -2.21 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -1.06 | |||||
Beneish M-Score | -3.47 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.1 | |||||
3-Year EBITDA Growth Rate | 40.2 | |||||
3-Year EPS without NRI Growth Rate | 36.5 | |||||
3-Year FCF Growth Rate | 41.9 | |||||
3-Year Book Growth Rate | -35.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -25.62 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -20.11 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 19.03 | |||||
9-Day RSI | 20.05 | |||||
14-Day RSI | 24 | |||||
3-1 Month Momentum % | -1.71 | |||||
6-1 Month Momentum % | -13.96 | |||||
12-1 Month Momentum % | -4.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.37 | |||||
Quick Ratio | 1.37 | |||||
Cash Ratio | 1.24 | |||||
Days Sales Outstanding | 53.76 | |||||
Days Payable | 628.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -30 | |||||
Shareholder Yield % | 2.95 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 82.18 | |||||
Operating Margin % | -103.66 | |||||
Net Margin % | -116.33 | |||||
EBITDA Margin % | -68.73 | |||||
FCF Margin % | -77.35 | |||||
OCF Margin % | -73.44 | |||||
ROE % | -87.36 | |||||
ROA % | -20.71 | |||||
ROIC % | -26.22 | |||||
3-Year ROIIC % | 149.87 | |||||
ROC (Joel Greenblatt) % | -92.6 | |||||
ROCE % | -34.04 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.75 | |||||
PB Ratio | 3.7 | |||||
Price-to-Tangible-Book | 3.86 | |||||
EV-to-EBIT | -1.22 | |||||
EV-to-EBITDA | -1.81 | |||||
EV-to-Revenue | 1.25 | |||||
EV-to-Forward-Revenue | 12.07 | |||||
EV-to-FCF | -5.01 | |||||
Price-to-GF-Value | 0.48 | |||||
Earnings Yield (Greenblatt) % | -82.19 | |||||
FCF Yield % | -29.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cellectis SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 48.465 | ||
| EPS (TTM) (€) | -0.558 | ||
| Beta | 4.5808 | ||
| 3-Year Sharpe Ratio | 0.47 | ||
| 3-Year Sortino Ratio | 1.52 | ||
| Volatility % | 70.58 | ||
| 14-Day RSI | 24 | ||
| 14-Day ATR (€) | 0.233119 | ||
| 20-Day SMA (€) | 2.48125 | ||
| 12-1 Month Momentum % | -4.33 | ||
| 52-Week Range (€) | 1.093 - 4.84 | ||
| Shares Outstanding (Mil) | 100.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cellectis SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cellectis SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-03-19 08:00 | In 181 days | ||
| Annual report for 2026 | 2027-03-19 | In 180 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-19 | In 180 days | ||
| Jefferies Global Healthcare Conference | 2026-11-16 | In 57 days | ||
| Guidance call for 2026 | 2026-11-10 | In 51 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 47 days | ||
| Guidance call for 2026 | 2026-09-15 12:50 | 1.51 (-14.59%) | ||
| Wells Fargo 21st Annual Healthcare Conference | 2026-09-10 | 2.74 (-0.87%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 2.48 (+2.14%) | ||
| General meeting for 2025 | 2026-06-25 14:30 | 2.47 (-3.22%) |
Show
Entries
Cellectis SA Frequently Asked Questions
What is Cellectis SA(XPAR:ALCLS)'s stock price today?
The current price of XPAR:ALCLS is €1.31. The 52 week high of XPAR:ALCLS is €4.84 and 52 week low is €1.09.
When is next earnings date of Cellectis SA(XPAR:ALCLS)?
The next earnings date of Cellectis SA(XPAR:ALCLS) is 2026-11-06 Est..
Does Cellectis SA(XPAR:ALCLS) pay dividends? If so, how much?
Cellectis SA(XPAR:ALCLS) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers